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Abstract
Background While large-to-giant pituitary adenomas (PAs)
may be safely removed by experienced surgeons through a
single route, the procedure is technically challenging. We
present the outcome of a simultaneous combined transcranial
and transsphenoidal approach and discuss its applications.
Methods A retrospective review was conducted on 12
consecutive patients. Surgical complications, visual and
endocrinologicalfunctions,andtumourcontrolwerereviewed.
Results There were four men and eight women, with a
mean age of 47.6 years. All but one patient had non-
functioning PAs. The mean tumour height was 4.1 cm
(range: 2.3–5.5). The predominant presenting symptoms
were visual field loss in eight patients, headache in three
patients and mental confusion in one patient. There was no
operative mortality. Post-operative cerebrospinal fluid leak-
age occurred in one patient. Five of the eight patients who
presented with visual field loss achieved full recovery, and
three had partial improvement. Two patients developed
permanent diabetes insipidus after surgery. Panhypopitui-
tarism occurred in one patient. Gross total removal (GTR)
was achieved in five, and subtotal removal (STR) in seven
patients. Seven patients received post-operative external
irradiation. All patients who had GTR remained tumour-
free and all those with STR had stable diseases after a mean
follow-up period of 53.1 months (range: 14.1–92.1).
Conclusion The simultaneous ‘above and below’ approach is
a safe and effective surgical strategy for large-to-giant PAs,
particularly when expertise in endoscopic transsphenoidal
surgery isunavailable. Its use,however, shouldbe limited to a
carefully selected group of patients, and tailored to individual
user’s expertise and experience.
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Introduction
Surgery for large-to-giant pituitary adenomas (PAs) is
technically challenging. Although the transsphenoidal ap-
proach has been widely adopted as a safe and effective
method for the removal of the majority of PAs, large lesions
may still present with considerable difficulties [1, 5, 8, 12,
13, 35]. Some of the large PAs may have a fibrous
consistency or an ‘hour-glass’ configuration, rendering
complete removal through the transsphenoidal route alone
difficult and hazardous. With incomplete removal, a
residual suprasellar tumour mass may be complicated by
haemorrhages at the early post-operative period, resulting in
acute hydrocephalus or optic nerve compression. The
transcranial approach is effective for the removal of a
suprasellar tumour mass but provides only limited visual-
ization of the intrasellar region. Since some of the large PAs
may be highly vascular, a direct transcranial attack may be
associated with significant bleeding within the intradural
space. Previous studies have reported high operative
mortality and morbidity rates using the transsphenoidal or
the transcranial approach alone [9, 14, 31, 32].
Several alternative approaches have been described,
including the extended endoscopic transsphenoidal approach
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DOI 10.1007/s00701-011-1029-y[4, 17], the staged transsphenoidal approach [1], the staged
transcranial-transsphenoidal approach [2], the combined
endoscopic transsphenoidal transventricular approach [10,
24, 25], and the simultaneous combined transcranial and
transsphenoidal approach [2, 7, 19]. The latter, in particular,
has the advantage of achieving radical tumour removal in a
single setting of general anaesthesia. We report our experi-
ences with this simultaneous ‘above and below’ technique,
and discuss its advantages and limitations.
Materials and method
A retrospective study was conducted on 12 consecutive
patients who underwent simultaneous combined micro-
scopic transsphenoidal and transcranial surgery for the
removal of PAs between January 2000 and December 2008.
The diagnosis of PA was made on magnetic resonance
imaging (MRI) and confirmed histologically. All giant PAs
(>4 cm in height) were approached with this technique
during the study period. For large PAs (>2 cm and <4 cm in
height), this approach was used when there was significant
lateral suprasellar or third ventricular tumour extension,
and/or an hourglass configuration.
The anatomical classification of PA described by Wilson
et al. [34] was adopted. The relationship of the PA to the
sella and sphenoidal sinus was graded as I (normal sella), II
(enlarged sella), III (localized sellar perforation), IV
(diffuse sellar destruction), and V [cerebrospinal fluid
(CSF) or blood-borne spread]. Extrasellar extension was
staged as 0 (none), A (occupying cistern), B (third
ventricular obliteration), C (grossly displaced third ventri-
cle), D (intracranial parasellar extension), and E (extradural
parasellar extension).
Patients’ pre-operative and post-operative (6-month)
visual and endocrinological functions, and surgical compli-
cations were reviewed. The first follow-up MRI was
performed three months after surgery. Gross total removal
(GTR) and subtotal removal (STR) were defined as the
absence or presence of contrast-enhancing lesions on the
first post-operative MRI, respectively. Thereafter, MRI was
performed 12-monthly for patients with GTR, and 6-
monthly for those with STR. Tumour control and the
patients’ Karnofsky Performance Score (KPS) were
assessed upon the latest follow-up.
Surgical technique
The tumour was approached both transcranially and trans-
sphenoidally under a single setting of general anaesthesia.
Prophylactic broad spectrum antibiotics (ceftriaxone and
metronidazole) were given on induction and continued for 3
days post-operatively. Each of the transsphenoidal and
transcranial phases had its own surgeon, scrub nurse,
operating microscope and set of instruments. The trans-
sphenoidal surgeon stood on the right side of the patient
while the transcranial surgeon was seated at the head end.
The two operative fields were separate by a vertical drape
to minimize contamination.
The transcranial approach was conducted through the
anterior interhemispheric route (ten patients) or the sub-
frontal route (two patients). The patient’sh e a dw a s
positioned using a Mayfield clamp in the neutral position
for the former, or turned to the side for the latter. The
transsphenoidal phase was performed using either the
sublabial transseptal route (ten patients) or the transnasal
route (two patients).
After the initial opening, two operating microscopes
were brought into position (Fig. 1). The tumour was
exposed on the cranial side, but every effort was made to
avoid breaching the tumour capsule in order to minimize
the amount of bleeding within the subarachnoid space. The
cranial surgeon’s role was to deliver the tumour down
towards the sphenoidal sinus, to dissect the tumour capsule
from adjacent intradural structures, and to protect the latter
against the transsphenoidal surgeon’s manipulations, which
may at times extend well up rostrally. The tumour capsule
was opened on the transsphenoidal side, followed by
tumour debulking with suction and curettage. In all of our
cases, the intrasellar and intradural tumour bulks were
removed completely. Figure 2 illustrates tumours that were
removed using this technique.
The subsequent skull base defect was repaired with
abdominal fat graft. Again, the cranial surgeon served to
prevent against over-enthusiastic packing by the trans-
sphenoidal surgeon. The rest of wound closure was
performed in the standard manner. A subgaleal suction
Fig. 1 The setting in the operating room, with two microscopes
positioned to allow the simultaneous participation of the transcranial
and transsphenoidal surgeons
1402 Acta Neurochir (2011) 153:1401–1408drain was inserted on the cranial side, and the nasal
passages were packed for one to two days. No lumbar
drain was used. All patients received post-operative care in
the intensive care unit. Except for those patients who had
previous irradiation therapy, all were offered post-operative
fractionated external irradiation as adjuvant treatment.
Results
Patient characteristics
There were four (33.3%) men and eight (67.7%) women,
with a mean age of 47.6 years (range: 32–79) (Table 1).
Fig. 2 Pre-operative contrasted
T1-weighted MRI studies illus-
trating tumours which were re-
moved using the combined
technique. The patient numbers
correspond to those in Table 1. a
Patient 4, b patient 5, c patient
9, d patient 11, e patient 12
Acta Neurochir (2011) 153:1401–1408 1403Eleven patients had non-functioning PAs and one had a
growth-hormone-secreting tumour. The mean tumour
height was 4.1 cm (range: 2.3–5.5). Nine were grade III
tumours and three were grade IV tumours. The numbers of
stage C, D and E tumours were three, two and seven,
respectively. Three cases were recurrent tumours with
previous transsphenoidal surgery and radiotherapy per-
formed. The predominant presenting symptoms were visual
field loss in eight, headache in three, and mental confusion
in one patients.
Operative procedures and complications
The transcranial approach was anterior interhemispheric in
ten patients and subfrontal in two patients (Table 2). The
transsphenoidal approach was sublabial transseptal in ten
patients and transnasal in two patients. The mean operation
time was 370 min (range: 210–460).
There was no operative mortality. One patient died
28 months after surgery due to an unrelated cause. One
patient (8.3%) had post-operative CSF leakage, which was
successfully treated with lumbar drainage. One patient
(8.3%) developed deep vein thrombosis without pulmonary
complication, and was successfully managed with an
inferior vena caval filter and anticoagulation. No patient
suffered from meningitis, hydrocephalus or new onset of
cranial nerve palsy.
Of all eight patients who presented with visual field loss,
five (62.5%) achieved full visual field recovery, and three
(37.5%) had partial improvement. None experienced
worsening of vision. All four patients who presented with
headache and confusion had symptomatic improvement
after surgery. Four patients developed diabetes insipidus
(DI) after surgery—two were transient (16.7%) and two
permanent (16.7%). Panhypopituitarism occurred in one
patient. Three other patients had new onset of isolated
anterior pituitary deficiencies. All patients had KPS of 70 or
above upon the last follow-up.
Tumour control
Based on the first post-operative MRI, GTR was achieved
in five (41.7%, all stage C or D lesions), and STR in seven
patients (58.3%, all stage E lesions). Three patients
received previous external radiotherapy and were not
offered further irradiation. Of the remaining nine patients,
seven received post-operative fractionated external irradia-
tion and two declined it. The mean follow-up period was
53.1 months (range: 14.1–92.1). Upon the last follow-up,
all five patients who had GTR remained tumour-free, whilst
all patients with STR had stable residual diseases. The one
patient with acromegaly had STR and continued to receive
bromocriptine for biochemical control.
Discussion
Large and giant PAs are difficult to remove safely. The
operative mortality rates have been reported to be as high as
25% for transcranial resection and 14% for transsphenoidal
resections [31]. Advancement in neurosurgical techniques
has led to an improvement in outcome. Sinha et al. [28]
Table 1 Patient characteristics and operative procedures
Patient
no.
Sex/age
(years)/
Symptoms Tumor size
(cm)
a
Tumor
grade
b
Cranial
approach
Transsphenoidal
approach
Extent of
removal
Operation time
(mins)
1 F/54 BTH 3.0×3.2×4.5 III C AIH Sublabial GTR 420
2 F/45 HA 2.9×2.5×4.4 III E Subfrontal Sublabial STR 360
3 M/41 HA 2.8×2.3×2.3 III D Subfrontal Sublabial GTR 400
4 M/62 BTH 3.0×4.1×5.2 III D AIH Sublabial GTR 380
5 F/62 Acromegalic features, BTH 3.3×2.6.3.6 III E AIH Sublabial STR 460
6 M/47 HA 3.0×3.5×5.5 IIIE AIH Sublabial STR 370
7 F/32 BTH 3.0×3.7×3.1 III E AIH Transnasal STR 380
8 F/65 BTH 3.2×2.2×2.9 III E AIH Sublabial STR 350
9 F/58 BTH 3.3×2.2×5.0 IV C AIH Sublabial GTR 450
10 F/52 BTH 3.6×4.4×4.6 IV E AIH Sublabial STR 210
11 M/79 Confusion 2.0×1.8.×2.8 III C AIH Transnasal GTR 300
12 F/34 BTH 3.7×3.6×5.3 IV E AIH Sublabial STR 360
AIH anterior interhemispheric, BTH bitemporal hemianopia, GTR gross total removal, HA headache, RT external radiotherapy, STR subtotal
removal
aWidth × length × height
bModified Hardy’s grading staging
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PAs. Near-total (>90%) tumour removal was achieved in
74% and improvement of vision in 53% of patients. The
mortality and morbidity rates were 4.4% and 14%,
respectively. Xue-Fei et al. [35] treated 54 patients with
large PAs using a variety of surgical approaches and
achieved complete tumour removal in 21% of cases. The
peri-operative mortality rate was 7.9%. In another series of
111 patients, Mortini et al. [21] reported a mortality rate of
2.7%. The incidences of ‘major’ complications (e.g. cranial
nerves, hypothalamic and vascular injuries, CSF leakages
and tumour haemorrhages), and ‘minor’ complications (e.g.
endocrinological) were 18% and 26%, respectively. Using
the same categorization, the incidences of ‘major’ and
‘minor’ complications in our present series were compara-
ble at 8.3% and 25%, respectively. The extent of removal in
our series, however, was comparatively lower, which was
probably due to our conservative approach towards tumours
within the cavernous sinuses.
The transsphenoidal approach is the treatment of choice
for the majority of PAs. But for tumours that arise in or
extend into the suprasellar region, transsphenoidal surgery
is generally contraindicated when there is a normal-sized
sella turcica, normal pituitary function, or adherence of the
tumour to major intracranial structures [6, 12, 14, 18]. A
tumour that is fibrous in consistency or has an hour-glass
configuration may also be difficult to remove completely
with a single transsphenoidal procedure [20]. Lumbar
subarachnoid saline or air injection may be used to facilitate
the descent of the suprasellar tumour bulk into the sella, but
the method is effective only in a subgroup of patients [29,
37]. In a prospective study, Honegger et al. [11] demon-
strated that the vertical intracranial extension, and an
irregular or multilobular configuration, were significant
and independent predictors for incomplete resection. To
address this, the two-staged transsphenoidal approach has
been advocated, in which, after the removal of the
intrasellar tumour component, the suprasellar residual
tumour was given time to descend and then removed by a
second-stage transsphenoidal procedure [1, 26, 31]. The
disadvantages of this approach include the need for two
operations and the potential risks of tumour swelling and
haemorrhages after the first-stage surgery.
The introduction of endoscopic transsphenoidal surgery
has revolutionized the treatment of sellar tumours [4]. It has
been shown to be safe and effective, and is now an arguably
standard therapy for the majority of PAs. But despite the
vastly improved illumination and visualization provided by
Table 2 Patients’ post-operative outcome
Patient
no.
Visual
function
New permanent
hormonal deficit
Surgical
complication
Post-
op RT
Tumour
status
KPS FU duration
(months)
Remarks
1 Normal DI, ↓ACTH None Yes Tumour-
free
90 109 None
2 Normal None None No Stable
residue
90 104 Recurrence after previous
transsphenoidal removal and RT
3 Normal None None No Tumour-
free
90 105 Recurrence after previous
transsphenoidal removal and RT
4 Normal DI None Yes Tumour-
free
80 28 Died 28 months later from unrelated
cause
5 Residual left
HeAn
Panhypopituitarism None Yes Stable
residue
90 93 Biochemical remission with
bromocriptine
6 Normal None CSF leakage Yes Stable
residue
90 65 None
7 Normal None None No Stable
residue
100 63 Patient refused RT
8 Improved
BTH
None None No Stable
residue
80 55 Recurrence after previous
transsphenoidal removal and RT
9 Normal ↓TSH Deep vein
thrombosis
Yes Tumour-
free
100 54 Deep vein thrombosis treated with
caval filter.
10 Residual left
HeAn
↓ACTH None Yes Stable
residue
100 24 None
11 Normal None None No Tumour-
free
70 24 Patient refused RT
12 Normal None None Yes Stable
residue
100 26 None
ACTH adrenocorticotropic hormone, BTH bitemporal hemianopia, CSF cerebrospinal fluid, DI diabetes insipidus, FU follow-up since surgery,
HeAn hemianopia, KPS Karnofsky Performance Score, RT external radiotherapy, TSH thyrotropic stimulating hormone
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single-stageremovalbyalimitednumberofexpertsonly[30].
Wang et al. [33] reported an 80% total resection rate in a
series of 64 patients without mortality or tumour recurrence.
Similarly, Sanai et al. [27] reported a GTR rate of close to
50%, with no incidence of CSF leakage, new panhypopitui-
tarism or worsening of vision. Nakao et al. [23]t r e a t e d4 3
patients using the endoscopic endonasal approach and an
intracapsular resection technique. Gross total removal was
achieved in close to 50% of cases and there was no major
complication. While the indications for endoscopic pituitary
surgery are expanding, its use and limits for the treatment of
huge PAs are yet to be defined. The extended endoscopic
transsphenoidal approach, in particular, is a technically
demanding technique. It requires specialized and advanced
training, and may not be readily acquired by surgeons
without the necessary case volume [4].
For many, the transcranial approach continues to play a
role in the management of PAs inaccessible from the
transsphenoidal route alone [36]. When compared with the
transsphenoidal approach, there is a trend towards greater
visual improvement, but the benefit may be offset by a
greater risk of post-operative pituitary dysfunction [22].
The disadvantages of the transcranial approach include the
amount of brain retraction required and the limited
visualization of the intrasellar area [
15]. In our experience,
a transcranial resection of vascular tumours may also be
associated with significant bleeding within the intradural
space. This may further obscure the surgical view, and
potentially increase the risks of brain swelling and
hydrocephalus. One of the advantages of our simultaneous
combined approach is that tumour bleeding would occur
predominantly on the transsphenoidal side. The transcranial
surgeon only serves to deliver the tumour bulk towards the
sella, and to protect the intradural structures.
Loyo et al. [19] first described the combined supra-sellar
and infra-sellar approach in 1984 for the resection of very
large PAs, and advocated it as superior to either the
transsphenoidal or the intracranial approach alone. Case
reports on the use of the ‘above and below’ approach for a
large craniopharyngioma [16], and a PA with lateral
ventricle extension have been described [10]. To our
knowledge, there are two reported case series on the
combined approach for large-to-giant PAs. Alleyne et al.
[2] reported a GTR rate of 40% in a cohort of ten patients.
More than half of those who presented with pre-operative
visual field loss experienced complete recovery. Permanent
DI occurred in 20% of patients. In D’Ambrosio et al.’s
series [7], GTR was achieved in six out of 11 patients
(55%). Seven patients (64%) experienced visual improve-
ment post-operatively and no major complication occurred.
Panhypopituitarism was observed in four and persistent DI
in two patients. The authors of these two series focused
mainly on early operative outcomes but not tumour control.
Our present study yielded similar early outcomes. In
addition, we were also able to demonstrate satisfactory
medium-term tumour control. Admittedly, the use of up-
front fractionated external irradiation, instead of radio-
surgery, in our series warrants careful scrutiny in view of
the former’s potential side-effects. This is a limitation of
our treatment paradigm that needs to be improved.
Conceptually, we consider this technique to be a
posterior extension of that of craniofacial resection for
anterior skull base tumours, in that lesions which occupy
two adjoining skull base compartments are best approached
simultaneously from both compartments for maximal
tumour removal and safety [15]. Although pathologically
very different, these two disease groups may exhibit similar
morphological features, such as close adherence to intra-
cranial structures, irregular configurations and extensive
skull base destruction. Technically, we favour the anterior
inter-hemispheric route for the transcranial phase because it
provides a better view of the parasellar region bilaterally.
The subfrontal or pterional route, on the other hand,
requires some head-turning, which may potentially disori-
entate the transsphenoidal surgeon.
One of the main goals of surgery for huge PAs is optic
nerve/chiasm decompression, for which the combined
approach appears to be a safe and effective method. The
main advantages of our technique include the need for only
one procedure, the protection offered by the transcranial
surgeon, and the avoidance of complications potentially
caused by any residual suprasellar tumour bulk. The main
disadvantages include the involvement of two operative
fields, the doubling of staff and instruments required, the
long operating time, and the potential complications of a
craniotomy. The need for two operating microscopes,
however, may be obviated by the use of endoscopes for
the transsphenoidal phase of the procedure. More recently,
an alternative ‘above and below’ approach has been
described by several authorities for the treatment of PAs
with significant third ventricular extensions. It uses a
simultaneous endoscopic transsphenoidal-transventricular
technique and therefore obviates the need for a craniotomy
[10, 24, 25].
In terms of tumour control, stage C (grossly displaced
third ventricle) and D (intracranial parasellar extension) are
potentially amenable to total removal with our technique;
stage E (extradural parasellar extension) lesions may
require a more extensive extradural approach. However,
being a retrospective case series, this report may suffer
from case selection bias, suboptimal data collection, and the
lack of a control cohort for outcome analysis. The optimal
treatment of large-to-giant PAs is likely to require a more
tailored approach, based on individual patients’ conditions
and the surgeons’ experiences and abilities. A multi-
1406 Acta Neurochir (2011) 153:1401–1408modality management strategy should be adopted to take
full advantages of the benefits provided by surgery and
radiotherapy [8]. The use of intra-operative MRI may also
significantly improve resection rate and safety [3]. Our
combined approach represents only one of the many
surgical strategies that can be used in dealing with these
challenging PAs, particularly when expertise in endoscopic
surgery is unavailable.
Conclusion
Large and giant PAs are challenging lesions. Although many
experienced surgeons would be able to remove these tumours
endoscopically through the transsphenoidal route alone, the
necessary expertise is not easy to acquire. The present study
demonstrates that the simultaneous transcranial transsphenoi-
dal approach is a safe and feasible alternative. It requires
teamwork and more readily available technical skills from the
transcranial and transsphenoidal surgeons. Its use, however,
should be limited to a carefully selected group of patients, and
tailored to individual users’ expertise and experiences.
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Comment
In managing a huge and multilobed tumour, the surgeon accepts that the
now generally adopted transsphenoidal approach is going to run the risk
ofleavingbenigntumourinthesuprasellarspaceand,ofcourse,invading
the cavernous sinus and that residual will cause problems with swelling
and haemorrhage in a few. The question is how to manage them.
I can accept the occasional need to link cranial and transsphenoidal
surgery, but my problem is why there is a need to do them both
together, exactly at the same time. Why not do the transsphenoidal and
go on, if absolutely necessary, at the same sitting. The transsphenoidal
is so quick, and all I could see is the cranial part getting in the way.
Michael Powell
London, UK
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